Dong Xie, PhD

Founder, Chairman, CSO

PhD John Hopkins Univ.

Executive Director Biocalorimetry Center at John Hopkins; Director Biophysics Lab at National Cancer Institute/NIH

Global Project Leader and R&D Director at Tibotec (acquired by J&J), led three novel anti-HIV drug development

CJ Wang, PhD

Board Director, CEO

PhD College of Pharmacy, Univ. of Kentucky 

>20+ years R&D and business development experience in US

VP BD at Vivus (Nasdaq: VVUS), Abmaxis (acquired by Merck) and TaiGen Biotech; VP Marketing and BD at Cellomics; Director BD and M&A at Packard Bioscience; Principal Scientist at Merck

RJ Lu, PhD

Board Director, CTO

PhD Nankai Univ., Postdoc Northeastern Univ. / Harvard Medical School; Sr. postdoctoral fellow at NCI 

Principal Research Investigator / Project Leader at Sequoia and Trimeris; Senior Scientist at Tibotec

Led and participated in CMC development of several anti-HIV drugs including T-20 and Darunavir>

Michael Hu

CMO

MD, MS pharmacology, Fudan Univ. Medical School

20+ years experience in clinical development and medical affairs; Former Head of Medical at Bayer (China)

Qi Shao

SVP & CFO

BS economics Southeastern Univ.  MS Finance Shanghai Univ.

10+ years experience in finance, auditing, taxation, investment and M&A at BASF and Continental 

Hangzhou LV

SVP Mktg. & Sales

BS Lanzhou Univ., MBA Nanjing Univ.

20+ years of marketing, sales, and market access experience at Pfizer (China) and Novartis (China)

Michael Wang

SVP Head of Infectious Diseases Th

PhD Brandeis Univ., Postdoc Harvard Medical School, MBA Golden Gate Univ 

25+ years R&D experience in infectious diseases：VP BD China, Senior Fellow Research at Brii Bio；Founder, CEO, CSO at Prelude Pharmaceutical Ltd；Senior Scientist at Gilead